Dear Sir:
The results obtained in the impressive study by Stephenson et al (1) are surprising and frustrating to desperate clinicians who have not succeeded in increasing serum 25-hydroxyvitamin D concentrations (SVDCs) in their cystic fibrosis (CF) patients. The failure of oral supplements to effect such is widely published (2) (3) (4) . In search of alternatives, we undertook a retrospective investigation to clarify the relative importance of vitamin D sources and came to remarkably different conclusions (5) .
SVDC data (n ҃ 474 measurements) collected annually over 4 consecutive years (2001) (2002) (2003) (2004) (2005) ) from 137 CF patients (mean age: 15.6 y; range: 0.5 mo to 42 y) were retrospectively evaluated. Plotted per month, these values depict an S-shaped curve convex from May to October (sunny) and concave in the following period (dark). Mean values in each period (sunny: 26.6 ng/mL; dark: 17.3 ng/mL) were significantly different from each other; however, this was not the case when values were compared with those of healthy controls during the same period (sunny: 28.6 ng/mL; dark: 18.8 ng/mL). A striking significant relation was found between SVDCs over the 4 y and the amount of sun hours in the preceding months. The SVDC curve constantly paralleled that indicating the hours of sunshine, with a delay of about 2 mo. It is interesting to note that all of these findings were valid in patients with exocrine pancreatic insufficiency and in those with pancreatic sufficiency, although the latter group (n ҃ 12) was too small to determine statistical significance. Another comparison also indicated the importance of the intestinal supply, because no significant difference was found between the SVDCs of 50 CF patients taking a daily oral supplement of at least 800 IU cholecalciferol and those of 50 patients matched for age and month of blood collection who were not taking supplements.
All of these findings suggest that endogenous vitamin D production in the skin, under the influence of sunlight, is an important source of this vitamin for CF patients. Sun exposure during the sunny months of the year should therefore be encouraged. In contrast, we found little evidence of an effect of oral supplements on SVDCs. These conclusions are not universally valid because the amount of sunlight largely depends on geographic latitude. However, under good conditions, sun exposure can be an inexpensive and convenient alternative to supplements for increasing SVDCs in CF patients.
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Reply to E Robberecht and S Vandewalle
Dear Sir:
We are grateful for Robberecht et al's interest and comments on our article (1) and appreciate the opportunity to respond to their letter. We agree with the authors that vitamin D deficiency is an international problem and that normalizing serum 25-hydroxyvitamin D concentrations in patients with cystic fibrosis (CF) has been challenging. Boyle et al (2) showed that, even with high doses of ergocalciferol (vitamin D 2 , plant form), serum 25-hydroxyvitamin D [25(OH)] concentrations do not increase as expected. Although our findings need to be confirmed in a randomized control trial, the results suggest that cholecalciferol (vitamin D 3 , animal form), at appropriate doses, can increase serum concentrations. Studies have shown that ergocalciferol does not increase serum 25(OH)D concentrations as efficiently as does cholecalciferol, which may explain these divergent results (3, 4) . That is not to say that vitamin D 2 is completely ineffective, and supplementation of milk with ergocalciferol in the United States has successfully eradicated rickets. However, the dose of vitamin D needed to prevent rickets is 100 IU/d in infants with little sun exposure. The dose of vitamin D needed to maintain nutritional adequacy on the basis of serum 25(OH)D concentrations is much higher. Robberecht et al raise an excellent point that sunlight may be the most effective and efficient way to normalize serum 25(OH)D concentrations in general and in CF patients in particular. This is undoubtedly the most "natural" way to make vitamin D. As stated in our article, Gronowitz et al (5) showed that 10 min of ultraviolet B exposure 3 times/wk increased serum 25(OH)D to concentrations as high as 124 nmol/L after 24 wk, which is much higher than that attained by supplementation with either cholecalciferol or ergocalciferol. doses of oral cholecalciferol, but this is not evident in the CF literature published to date. Natural exposure to sunlight for vitamin D synthesis is affected by season and latitude, which perhaps makes it less reliable. Also, the focus on sunscreen use and skin protection at a very early age has most certainly decreased vitamin D synthesis over one's lifetime. The use of controlled sun exposure as a therapeutic option for vitamin D deficiency in CF patients should be explored in future trials. Furthermore, well-designed randomized clinical trials of vitamin D supplementation with cholecalciferol in CF patients are badly needed to answer the question of whether this therapy is effective in maintaining serum 25(OH)D concentrations above 75 nmol/L.
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